Syntex' Ticlid
Executive Summary
Story in "The Pink Sheet" (Dec. 17. T&G-1) on an advisory committee's recommendation for approval of Ticlid significantly understated the drug's effectiveness in reducing risk of nonfatal or fatal stroke over aspirin. The Syntex researcher said that Ticlid "significantly reduces the risk of nonfatal or fatal stroke over aspirin [by 47%] in the first year," not .7%.... Bristol- Myers Squibb's Videx: "The Pink Sheet" mistakenly said the product was Merck's (Dec. 10, p. 9).